Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel.

Slides:



Advertisements
Similar presentations
THE CHALLENGES & OPORTUNITIES OF ACCESS TO MEDICINES IN AFRICA Dr Pascoal MOCUMBI, orig Mozambique,High Representative EDCTP ABRASCO/WFPHA.
Advertisements

Partnerships for Health Reform Utilization and Expenditures on Outpatient Health Care by HIV Positive Individuals in Rwanda PHR Rwanda - Abt Associates.
National experiences of regular price monitoring Klara Tisocki, WHO/HAI medicine price project Towards equitable and affordable medicine prices policy.
Results of the Jordan medicine price and availability survey conducted in 2004.
Introduction of the Annual Report 1. Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5.
Medicine Prices Matter to People and Insurance Companies Margaret Ewen Health Action International.
Direct costs and availability of diabetes medicines in low-income and middle-income countries Birgit Volman 27/08/2008 Meeting on Access to Medicines for.
1 Paying the Price Margaret Ewen Health Action International Europe.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
August 27th Availability, Pricing and Affordability of Asthma Medicines Presentation for Meeting on Availability, Pricing and Affordability.
1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.
Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Completing the Medicine Price Data Collection form Presentation template for adaptation and use in medicine prices and availability survey training workshop.
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006.
1 Medicine Availability, Prices and Affordability in West Bengal, India (2004) DALIA DEY CUTS & CDMU.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Syria,2004 Medicine price survey in Syria, 2004 undertaken by Pharmaceutical Studies Directorate, Ministry of Health Presentation by Razan Sallouta WHO/HAI.
A MEDICINE PRICES SURVEY IN CHINA Presentation by Dr Xiaoxia Hu Research by Dr Sun Qiang and Dr Xiaoxia Hu June, 2006.
1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
Mohamed Izham Mohamed Ibrahim
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
The prices of medicines worldwide & how they are determined Margaret Ewen Health Action International Europe Co-ordinator WHO/HAI Project on Medicine Prices.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Price, availability and affordability of medicines international comparison of 29 surveys Presented by: Richard Laing World Health Organization, Geneva.
Essential Medicines & Pharmaceutical Policies DHS/EMRO WHO Perspective on Medicine Prices & Policies Meeting of Drug Board on Medicine Pricing Federal.
Medicine prices, availability, affordability and component prices Margaret Ewen Health Action International, The Netherlands Coordinator WHO/HAI Project.
Medicine Prices and Affordability Survey in West Bengal, India ( )
Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.
Innovation data collection: Advice from the Oslo Manual South East Asian Regional Workshop on Science, Technology and Innovation Statistics.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
Medicine prices: a WHO/Health Action International collaboration The approach, some results, and implications for policy to improve the affordability of.
2011 WINNISQUAM COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=1021.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Donald T. Simeon Caribbean Health Research Council
Global impact of medicine shortages Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada June.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
1 Generating reliable evidence: measuring medicine prices and availability Dr Richard Laing Department of Essential Medicines and Pharmaceutical Policy.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan WHO/HAI Project on Medicine Prices & Availability Cost Plus Price Setting.
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
IMPACT OF EDUCATIONAL INTERVENTION ON PRESCRIBING BEHAVIOUR AND COST OF THERAPY IN BRONCHIAL ASTHMA IN COLONY HOSPITALS OF DELHI Kotwani A, Gupta U, Suri.
Survey of the availability and prices of Children’s Medicine in Chhattisgarh State Dr. Antony K.R. Virendra Jain Puni Kokho Dr. Kamlesh Jain State Health.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
DOES REGISTRATION OF SEVERAL GENERICS TRANSLATE INTO MORE AND CHEAPER DRUGS FOR THE PATIENTS’ IN SRI LANKA? Fernandopulle BMR Senarathna SMDKG Department.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Medicines prices: measurement and findings in countries Richard Laing PSM - WHO Gilles Forte TCM - WHO Margaret Ewen HAI - Europe.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
WHO and the Global Fund harmonized tool for Pharmaceutical Country Profiles Richard Laing & Enrico Cinnella, November 2011.
WHO-Health Action International project on drug price comparisons A technical project of the WHO-Public interest NGO round table on access to medicines.
Efficiency of Public Procurement of Medicines in the Philippines Klara Tisocki, Douglas Ball Health Action International.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Availability of children’s medicines in Africa, 2007 Jane Robertson, Gilles Forte, Suzanne Hill.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Paying the price: Medicine prices, availability and affordability across the globe Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
A BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
WHO/Health Action International Project on Medicine Prices Margaret Ewen, HAI Europe Background and purpose of the project Technical approach to measuring.
Medicine prices and availability, evidence for policy
Presentation transcript:

Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel Chest Institute University of Delhi, Delhi

Global problems of medicines prices Medicines have variable and generally high prices, are unaffordable by poor patients and a major burden on government budget. Unlike people in developed countries, people in developing countries pay 'out of pocket for health care. Price of a medicine has impact on affordability and therefore access to essential medicines. Many low income countries do not have pricing policies. ….but, the prices of medicines are well above their production costs - so there is great scope for reduction

Need to measure the price of medicines Little is known about the prices people pay for medicines and how the retail prices are set Reliable information is required for more favourable purchasing agreements, better domestic distribution and pricing policies implementation/monitoring Improved price transparency empowers actors concerned with health and medicines policy Sound data influence sound policies and more affordable medicines

Background to the WHO-HAI project on Medicine Prices Absence of a standard methodology to monitor medicine prices, to obtain reliable, up-to-date information on drug prices and price comparison within countries Methodological difficulty of making international comparisons WHO-Public Interest NGO Roundtable on opportunity to launch such an initiative WHO in collaboration with Health Action International (HAI) published a manual in 2003 Medicine Prices: a new approach to measurement after field testing it in 9 countries

Designed to inform on: What price do people pay for essential medicines (core drugs)? Do the prices of these drugs vary in different sectors, e.g., public, private and other sector? Do the prices of medicines vary in different regions of a State/country? What is the difference in prices of originator brands and generically equivalent medicines? How do the prices of medicines in the different sectors of the State compare to international reference price (IRP)? What is the availability of the medicines in different sectors? How affordable are medicines for ordinary people? What is the level of various mark-ups which contribute to their retail prices?

Methodology – technical basis of the survey Collecting National Pharmaceutical Sector Data – to have a clear understanding of how pharmaceutical services are organized Identifying Sectors – The survey measures medicine prices in different sectors, public, private and other sectors Sampling – Systematic sampling of medicine outlets in at least 4 areas, with a minimum of 10 pharmacies per area

Selecting medicines – A short list of 30 core list of commonly used medicines in a predetermined strength and dosage form has been selected Supplementary list of medicines – to be included as per the local needs Collecting data on the price and availability of medicines. For each medicine data collectors collect for Innovator Brand (IB), Most Sold Generic (MSG) and Lowest Priced Generic equivalent (LPG, available at each facility) in each health facility and pharmacy Affordability is measured in terms of the daily wage of the lowest paid government worker Price components – All components of price from manufacturer to retailer are identified

Data analysis & interpretation Data entry is done in an excel workbook and it generates some automated analysis. Medicine prices are expressed in comparison to an IRP to facilitates international comparisons. Reference price acts as an external standard for evaluating the local price. WHO-HAI recommends using the MSH price ( Price are expressed in Median Price Ratio (MPR).

The MPR is the median unit price across the facilities surveyed in a sector (in local currency) divided by the international reference price (also in local currency) Hence, the MPR is a unit of measurement of price that ensures a standard approach for comparisons – the higher the MPR, the higher the price Automated summaries of data permit data analysis for price and availability comparison within sector, comparison between sector, treatment affordability and price composition

Rajasthan Survey The first survey was conducted (funded by WHO- HAI) in Rajasthan for measuring prices and availability of essential medicines from April-June Prices and availability of 36 medicines -27 from the core list and 9 medicines as supplementary list were analyzed. For each medicine data was collected for IB, MSG and LPG. Data was collected from three sectors –public, private and co-operative sector. Data was collected from Jaipur (State capital) and three other randomly selected regions – Ajmer, Bikaner and Kota.

In each area, 5 public facilities, 5 private and 5 co-operative pharmacies near the public facility were surveyed. Hence, a total of 20 public facilities, 20 private pharmacies and 20 co-operative pharmacies were surveyed in four regions of Rajasthan.

Rajasthan Results Public Sector – Mainly the LPG equivalents were available and the median MPR for procurement was acceptable – 0.96 Only a few categories of patients, e.g., Below Poverty Line (BPL) card holders, senior citizens, freedom fighters, destitute, widows and ex-service men are entitled for free medicines in public sector Private Sector – The median MPR for IB, MSG and LPG was 2.81, 2.72 and Not much difference in the price of IB and MSG but LPG was found to be 33% cheaper than MSG.

MPRs of few interesting medicines in Public and Private Sector

Few of the drugs were priced very high in the Private sector compare to Procurement price

Median Availability of medicines in Public, Private and Co-operative Sectors Public sector (n=20) Private sector (n=20) Co-operative sector (n=20) IB 0.0% MSG 0.0%82.5%72.5% LPG 40.0%95.0%90.0%

Affordability was measured in terms of daily wage (INR130) of lowest government worker Affordability of following 6 diseases in the private sector –Peptic ulcer (ranitidine tab 150mg x 2 for 30 days) –Diabetes (glibenclamide tab 5 mg x 2 for 30 days) –Hypertension (hydrochlorothiazide tab 25 mg daily for 30 days) –Pediatric Respiratory Infection (co-trimoxazole susp 10ml daily for 7 days) –Gonorrhoea (ciprofloxacin 500mg tab) –Asthma (salbutamol inhaler 1 inhaler mg/dose, 200 doses)

Conclusions from Rajasthan Survey The government of Rajasthan purchases medicines at a reasonable price for patients who are eligible for free medicines at public health facilities but the availability of medicines is low Majority of population purchase medicines from the private sector almost half the medicines surveyed were priced less than twice the international reference price Price of albendazole, diazepam, and diclofenac in the private sector was 10, 26 and 14 times the procurement price in the public sector, indicating very high margins for wholesalers and retailers In India, not much regulation on the prices of medicines and government rely mainly on the forces of market competition.

The lowest price generics that are otherwise manufactured in the country were generally not found at the pharmacies surveyed There was not much variation in price of the same medicine in different geographical areas of Rajasthan Availability of drugs for HIV/AIDS was poor in all sectors Treatment of diseases looks affordable but a very small percentage is employed in government sector, salary is very less in unorganized sector, treatment challenging for unemployed and if multiple illnesses in a family or the earning member is ill.

More surveys to validate the results WHO-HAI conducted a pre survey workshop at Hyderabad, India in April04 In 2.5 days workshop detail methodology and field work was conducted Participants submitted their proposal and 6 proposals were cleared and funded by WHO-HAI, Guided by Richard Laing (WHO), Marg Ewen (HAI) and Technical coordinator, Anita Kotwani

Six more surveys were conducted (Sept04 – Jan05)with WHO-HAI Methodology State/CityDistrictsPublic Facilities Private Facilities No. of Core Drugs Surveyed Chennai Harayana Karnataka Maharashtra(1) Maharashtra(2) West Bengal

Public Sector Procurement Price The median MPRs in ascending order were – Chennai Haryana – 0.33 Maharashtra(1) – 0.41 Maharashtra (2) – 0.41 West Bengal Karnataka – 0.48

Availability in Public Sector The median availability for core medicines was – West Bengal – 0.0% Maharashtra (1) – 3.3%, Haryana – 10.0% Maharashtra (2) – 10.5% Karnataka – 12.5% Chennai – 30.0%

Private Sector Medicine Price The median MPRs of - IB ranged from 1.74 – 4.38 MSG ranged from 1.3 to 1.69 LPG ranged from 1.3 to 1.84 There was not much variation in price of medicine from one state to another Difficult to find out the mark ups, not much transparency in the system

Availability in Private Sector The median availability of IB, MSG and LPG was found to be – 0.0 %, 95.0 % and 95.0% in Chennai 0.0%, 50.0% and 60.0 % in Haryana 2.5 %, 50.0% and 62.5 % in Karnataka 3.3%, 66.7 % and 73.3 % in Maharashtra (1) 2 %, 47.9 % and 51.0 % in Maharashtra (2) 22.9 %, 74.3 % and 77.1 % in West Bengal

Important findings observed for certain individual medicines The average MPRs for IB, MSG and the LPG of ciprofloxacin in private pharmacies was 4.47, 6.1 and 3.38 respectively; the average procurement price in the public sector was 1.1 Ranitidine - another scheduled drug The average MPR for all types - IB, MSG and LPG - was 0.48 and the average procurement MPR in the public sector was 0.31 Procurement price of diazepam was 0.50, whereas the average MPR for the LPG in the private sector was 9.2

Conclusions of the surveys Procurement price is very good in public sector at all sites. Availability is poor in public sector. Poor patients are forced to buy medicines from private sector due to non availability in public sector. Prices of certain medicines are high in private sector. Margins of certain medicines in private sector are very high – needs further study.

Takeaways… Methodology is simple, reliable and robust for collecting and analyzing medicine prices across healthcare sectors both within and between countries. Surveillance of medicine prices using this methodology is a useful tool for international medicine price comparison. Baseline data generated from these surveillance could be used by regulatory authorities and policy makers for suitable interventions to decrease medicine prices and increase availability and affordability of essential medicines Medicine prices should be published regularly so that people are informed about medicine prices.

Thank you!